VMN

Respira Technologies, Inc. Rebrands as “QNOVIA”; Adopts Qnovia, Inc. as Corporate Name

Retrieved on: 
Tuesday, September 13, 2022
Biotechnology, Alternative Medicine, Other Health, Health, Pharmaceutical, Poseidon, Therapy, FDA, Altria Group, Inc. v. Good, Innovation, IND, Altria, News, COO, Technology, Pain management, CEO, Quigley, VMN, COPD, Smoking, CDER, Pharmaceutical industry, Asthma

The company is advancing to an IND submission and is securing financing for human clinical trials.

Key Points: 
  • The company is advancing to an IND submission and is securing financing for human clinical trials.
  • As the company advances, this rebranding will further differentiate the companys technology and products from others in the biotechnology space.
  • This news follows the recent appointment of Brian Quigley as CEO of the company.
  • The company was founded by Mario Danek in 2018 to build cutting-edge drug delivery platforms that improve patient outcomes through superior device technologies.

Former Top Altria Exec Takes the Reigns at Respira Technologies: Brian Quigley Is Appointed CEO

Retrieved on: 
Thursday, August 18, 2022
Alternative Medicine, Medical Devices, Health, General Health, Pharmaceutical, Biotechnology, Poseidon, FDA, CEO, Pain management, Quigley, Technology, Smoking, IND, Altria, Therapy, Cannabis, COO, COPD, VMN, Innovation, Pharmaceutical industry, Asthma

Respira Technologies, Inc.a clinical-stage company developing inhaled therapeutics for smoking cessation and drug delivery technologies to treat cardiopulmonary diseaseshas appointed former Altria Group executive and current Respira COO Brian Quigley as its new Chief Executive Officer.

Key Points: 
  • Respira Technologies, Inc.a clinical-stage company developing inhaled therapeutics for smoking cessation and drug delivery technologies to treat cardiopulmonary diseaseshas appointed former Altria Group executive and current Respira COO Brian Quigley as its new Chief Executive Officer.
  • Quigley spent 16 years at Altria Group, with seven years as President & CEO at Altrias Smokeless and Innovative Products/Vapor Businesses.
  • With Respira in the midst of securing financing for clinical trials, Danek made a significant change to the structure of the companys leadership team.
  • Respira is backed by venture firms Blue Ledge Capital, DG Ventures, Evolution VC Partners, and Poseidon Asset Management.

Respira Technologies, Inc. Announces Partnership With The Plough Center For Sterile Drug Delivery At The University Of Tennessee Health Science Center

Retrieved on: 
Tuesday, March 22, 2022
Poseidon, Daou Technology Inc., UTHSC, Private sector, VMN, University of Tennessee Health Science Center, Multimedia, Pain management, IND, Panel, View, CA, COPD, CEDR, FDA, University, Partnership, Pharmaceutical industry, Medical device, Asthma

Respira Technologies, Inc. is pursuing FDA authorization by CEDR as the first inhalable prescription smoking cessation therapy.

Key Points: 
  • Respira Technologies, Inc. is pursuing FDA authorization by CEDR as the first inhalable prescription smoking cessation therapy.
  • The Plough Center, a non-profit sterile drug delivery organization, provides best in class pharmaceutical drug product services to early-stage biotech and pharma companies advancing technologies that can have a significant impact on our society.
  • The RespiRxis a combination device where the sterile drug product is filled aseptically in a disposable cartridge which also includes the proprietary aerosol generating engine.
  • Maintaining sterility of the drug product and effectively complying with FDA's container closure requirements requires best in class capabilities.

Respira Technologies, Inc. announces Jasjit S. Ahluwalia, MD, MPH, MS as Chair of the company's newly formed Scientific Advisory Board.

Retrieved on: 
Tuesday, January 18, 2022
Poseidon, Coronavirus Scientific Advisory Board (Turkey), COPD, Research, NDA, Nicotine, Technology, NIH, Diabetes, CADRE, Investigational New Drug, Mortality, Publication, Tobacco, Addiction, Disease, Harm reduction, National Institute on Minority Health and Health Disparities, Smoker, Science, CA, Brown University, IDeA Networks of Biomedical Research Excellence, Death, CEO, VMN, Health equity, IND, Center, Public health, Daněk, Center for Drug Evaluation and Research, View, Pain management, Smoking, Associate, COBRE, Multimedia, Compass rose, Centers of Biomedical Research Excellence, Smoking cessation, FDA, Pharmaceutical industry, Asthma

LOS ANGELES, Calif., Jan. 18, 2022 /PRNewswire/ -- Respira Technologies, Inc. (Los Angeles, CA) announced today, the formation of its Scientific Advisory Board and named Dr. Jasjit ("Jas") S. Ahluwalia as Chair of the newly formed advisory board.

Key Points: 
  • LOS ANGELES, Calif., Jan. 18, 2022 /PRNewswire/ -- Respira Technologies, Inc. (Los Angeles, CA) announced today, the formation of its Scientific Advisory Board and named Dr. Jasjit ("Jas") S. Ahluwalia as Chair of the newly formed advisory board.
  • Danek added, "We are thrilled to name Dr. Ahluwalia as Chair and the founding member of our Scientific Advisory Board.
  • He represents one of the best and brightest scientific minds with decades of experience in studying nicotine addiction and cessation.
  • Respira is backed by venture firms: Blue Ledge Capital, Compass Rose, DG Ventures, Evolution VC Partners and Poseidon Asset Management.

Altasciences Chosen by Respira Technologies, Inc. as Drug Product Manufacturing Partner for the World’s First Inhaled Nicotine Replacement Therapy (NRT)

Retrieved on: 
Tuesday, December 14, 2021
Retail, Medical Devices, Health, Tobacco, Pharmaceutical, Biotechnology, Food, Medical writing, FDA, Smoking, VMN, Creativity, IND, Biostatistics, Food and Drug Administration, Drug discovery, Data management, Risk, CEO, Research, Biotechnology, API, CGMP, Operation, Drug development, Investment, Technology, Pharmaceutical industry, Fine chemical

Altasciences pharmaceutical contract manufacturing site in Philadelphia, PA, has been chosen by Respira Technologies, Inc. to manufacture proprietary drug products for the worlds first inhaled smoking cessation therapy.

Key Points: 
  • Altasciences pharmaceutical contract manufacturing site in Philadelphia, PA, has been chosen by Respira Technologies, Inc. to manufacture proprietary drug products for the worlds first inhaled smoking cessation therapy.
  • Respira also plans to create a larger platform approach for active pharmaceutical ingredient (API) delivery, taking advantage of the multi-drug capabilities of their proprietary platform drug delivery system.
  • Altasciences is agile, flexible, and quick, while providing the proven expertise and capability required for cGMP pharma drug product manufacturing.
  • For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions.

After a successful Pre-IND meeting with FDA, Respira Technologies, Inc. announces plans to submit an Investigative New Drug Application (IND) to FDA in 2022 as the world's first truly inhalable prescription smoking cessation therapy

Retrieved on: 
Tuesday, November 30, 2021
Poseidon, CDER, CEO, Review, Safety, Technology, Smoking, Death, NRT, Center for Drug Evaluation and Research, Nicotine, VMN, Founder, Smoker, Center, View, FDA, CA, Daněk, CDC, Engineering, Multimedia, Disease, Pharmaceutical industry

As a result, quitting "cold turkey" remains the #1 method of cessation for smokers trying to quit smoking.

Key Points: 
  • As a result, quitting "cold turkey" remains the #1 method of cessation for smokers trying to quit smoking.
  • Respira's combination device the RespiRxTM is the first truly patient-focused and ultra-portable handheld Vibrating Mesh Nebulizer (VMN) for local and systemic treatments.
  • The device is a handheld, portable with a pre-filled disposable drug-product containing cartridge that operates in any direction being held.
  • Respira has patents granted and multiple in review for its device design and drug product formulations.